Relative Strength Chart Genmab A/S Nasdaq

Stocks

Market Closed - Nasdaq Other stock markets 00:00:00 13/06/2026 +04			5-day change	1st Jan Change
25.08 ^USD	-0.63%		-0.28%	-18.57%

06-11	Genmab Says Subgroup Data for Follicular Lymphoma Treatment Shows 'Sustained' Efficacy Benefits	MT
06-11	Genmab A/S Presents EPCORE FL-1 Subgroup Data Demonstrating Consistent Efficacy And Safety Results For Epcoritamab In Combination With Rituximab And Lenalidomide R2 Across Relapsed Or Refractory Follicular Lymphoma Patients	CI

End-of-day quotes

		Sector	Change	5-day change	YTD change	1-year change	5-year change	Capi.	ST	MT	LT
	GENMAB A/S	Bio Therapeutic Drugs	-0.63%	-0.28%	-18.57%	+9.90%	-42.66%	15.4B	-	-	-